Login to Your Account

Other News To Note

Wednesday, July 11, 2012
• MDxHealth SA, of Liege, Belgium, said it expanded its collaboration with Merck KGaA, of Darmstadt, Germany, to cover the development and worldwide commercialization of MDxHealth's MGMT (methylguanine-DNA-methyltransferse) diagnostic test to identify glioblastoma patients who might be more likely to benefit from cilengitide, Merck's Phase III-stage integrin inhibitor.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription